EPEdmund A. Pribitkin

Edmund A. Pribitkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Edmund A. Pribitkin has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Douglas D. Leventhal

    Department of Otolaryngology-Head and Neck Surgery, Thomas Jefferson University Hospital, Philadelphia, PA 19107, USA

    3 shared publications
  • Edita Aksamitiene

    Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University, Philadelphia, USA

    3 shared publications
  • Jewel D. Greywoode

    Department of Otolaryngology Head & Neck Surgery, Facial Plastic and Reconstructive Surgery, Microvascular Reconstructive Surgery, Southern California Permanente Medical Group, Los Angeles, California

    3 shared publications
  • Ryan N. Heffelfinger

    Department of Otolaryngology – Head and Neck Surgery, Thomas Jefferson University, Philadelphia, USA

    3 shared publications
  • Waleed H. Ezzat

    Department of Otolaryngology - Head and Neck Surgery, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts

    3 shared publications
  • Brian J. O'Hara

    Thomas Jefferson University, Department of Pathology, Anatomy and Cell Biology, Philadelphia, PA, U.S.A.

    2 shared publications

Latest Publications

  • Open Access

    Towards universal chemosensory testing: needs, barriers, and opportunities

    by Steven D Munger, Kai Zhao, Linda A Barlow, Duncan Boak, Katie Boateng, Susan E Coldwell, Pamela Dalton, Richard L Doty, Jennifer E Douglas, Valerie Duffy, et al.

    Millions of people in the United States experience a reduced or distorted ability to smell or taste. Chemosensory disorders such as anosmia (the inability to smell), parosmia (distorted smell), or dysgeusia (altered taste) have major impacts on health and quality of life including difficulty sensing dangers such as fire or spoilage, a diminished palatability of food and drink that can negatively influence diet and nutrition, feelings of social isolation, and an increased incidence of frailty, anxiety, and depression. Smell or taste dysfunction can also be symptoms of other health issues, including sinonasal disease, cancer, or neurodegenerative disease. Aging adults are disproportionately affected. However, smell and taste function are not regularly assessed as a part of routine healthcare despite their prevalence and impact. This is a lost opportunity, as early detection of a chemosensory disorder would enable patients to obtain needed validation, education and support for their health challenge, could direct both patient and provider to treatment options, and may suggest underlying health issues that should be addressed. To better understand the current barriers to including chemosensory testing as a regular component of health care and to identify opportunities to overcome those barriers, the conference “Towards Universal Chemosensory Testing” was convened on November 5–7, 2023, in Philadelphia, PA. This conference brought together scientists, clinicians, patients, and other experts to discuss these issues and identify collective ways to overcome barriers to testing. This white paper—which is focused primarily on the US healthcare system—is the result of those discussions.


  • Open Access

    Design and Implementation of an Opioid Scorecard for Hospital System–Wide Peer Comparison of Opioid Prescribing Habits: Observational Study

    by Benjamin Heritier Slovis, Soonyip Huang, Melanie McArthur, Cara Martino, Tasia Beers, Meghan Labella, Jeffrey M Riggio, Edmund Deazevedo Pribitkin

    Background: Reductions in opioid prescribing by health care providers can lead to a decreased risk of opioid dependence in patients. Peer comparison has been demonstrated to impact providers’ prescribing habits, though its effect on opioid prescribing has predominantly been studied in the emergency department setting. Objective: The purpose of this study is to describe the development of an enterprise-wide opioid scorecard, the architecture of its implementation, and plans for future research on its effects. Methods: Using data generated by the author’s enterprise vendor–based electronic health record, the enterprise analytics software, and expertise from a dedicated group of informaticists, physicians, and analysts, the authors developed an opioid scorecard that was released on a quarterly basis via email to all opioid prescribers at our institution. These scorecards compare providers’ opioid prescribing habits on the basis of established metrics to those of their peers within their specialty throughout the enterprise. Results: At the time of this study’s completion, 2034 providers have received at least 1 scorecard over a 5-quarter period ending in September 2021. Poisson regression demonstrated a 1.6% quarterly reduction in opioid prescribing, and chi-square analysis demonstrated pre-post reductions in the proportion of prescriptions longer than 5 days’ duration and a morphine equivalent daily dose of >50. Conclusions: To our knowledge, this is the first peer comparison effort with high-quality evidence-based metrics of this scale published in the literature. By sharing this process for designing the metrics and the process of distribution, the authors hope to influence other health systems to attempt to curb the opioid pandemic through peer comparison. Future research examining the effects of this intervention could demonstrate significant reductions in opioid prescribing, thus potentially reducing the progression of individual patients to opioid use disorder and the associated increased risk of morbidity and mortality.

  • Open Access

    Standardized Pre-clinical Surgical Animal Model Protocol to Investigate the Cellular and Molecular Mechanisms of Ischemic Flap Healing

    by Edita Aksamitiene, Ryan N. Heffelfinger, Jan B. Hoek, Edmund Deazevedo Pribitkin

    Background: Some of the most complex surgical interventions to treat trauma and cancer include the use of locoregional pedicled and free autologous tissue transfer flaps. While the techniques used for these reconstructive surgery procedures have improved over time, flap complications and even failure remain a significant clinical challenge. Animal models are useful in studying the pathophysiology of ischemic flaps, but when repeatability is a primary focus of a study, conventional in-vivo designs, where one randomized subset of animals serves as a treatment group while a second subset serves as a control, are at a disadvantage instigated by greater subject-to-subject variability. Our goal was to provide a step-by-step methodological protocol for creating an alternative standardized, more economical, and transferable pre-clinical animal research model of excisional full-thickness wound healing following a simulated autologous tissue transfer which includes the primary ischemia, reperfusion, and secondary ischemia events with the latter mimicking flap salvage procedure. Results: Unlike in the most frequently used classical unilateral McFarlane’s caudally based dorsal random pattern skin flap model, in the herein described bilateral epigastric fasciocutaneous advancement flap (BEFAF) model, one flap heals under normal and a contralateral flap—under perturbed conditions or both flaps heal under conditions that vary by one within-subjects factor. We discuss the advantages and limitations of the proposed experimental approach and, as a part of model validation, provide the examples of its use in laboratory rat (Rattus norvegicus) axial pattern flap healing studies. Conclusions: This technically challenging but feasible reconstructive surgery model eliminates inter-subject variability, while concomitantly minimizing the number of animals needed to achieve adequate statistical power. BEFAFs may be used to investigate the spatiotemporal cellular and molecular responses to complex tissue injury, interventions simulating clinically relevant flap complications (e.g., vascular thrombosis) as well as prophylactic, therapeutic or surgical treatment (e.g., flap delay) strategies in the presence or absence of confounding risk factors (e.g., substance abuse, irradiation, diabetes) or favorable wound-healing promoting activities (e.g., exercise). Detailed visual instructions in BEFAF protocol may serve as an aid for teaching medical or academic researchers basic vascular microsurgery techniques that focus on precision, tremor management and magnification. Graphical


  • Open Access

    Novel, standardized pre-clinical surgical animal model to investigate the cellular and molecular mechanisms of ischemic flap healing

    by Edita Aksamitiene, Ryan N Heffelfinger, Jan B Hoek, Edmund Deazevedo Pribitkin

    Background Some of the most complex surgical interventions to treat trauma and cancer include the use of locoregional pedicled flaps and free autologous tissue transfer. While the techniques used for these reconstructive surgery procedures have improved over time, flap complications and even failure remain a significant clinical challenge. Animal models are useful in studying the pathophysiology of ischemic flaps, but when repeatability is a primary focus of a study, conventional in-vivo designs, where one randomized subset of animals serves as a treatment group while a second subset serves as a control, are at a disadvantage instigated by greater subject-to-subject variability.Results We present a novel, economical, and standardized pre-clinical animal model of excisional full-thickness wound closure and healing using axial pattern flaps that incorporates an anatomically named vascular pedicle. In this bilateral epigastric fasciocutaneous advancement flap (BEFAF) model, which simulates an actual clinical procedure of autologous tissue transfer, one flap heals under normal and a contralateral flap - under perturbed conditions or both flaps heal under conditions that vary by one within-subjects factor. Although we describe step-by-step methodological approach how to create such flaps as well as collect, process, and analyze flap survival data in larger size rodents, specifically, the rats (Rattus norvegicus), the BEFAF model is transferable and could be implemented in any mammalian species. We also stress the importance of taking and presenting high resolution histological stain images of the flaps that are indispensable for diagnostic result interpretation in the full-thickness wound healing studies.Conclusions BEFAFs may be used to investigate the spatiotemporal cellular and molecular responses to complex tissue injury and interventions simulating clinically relevant flap complications (e.g., secondary arterial, venous, or mixed ischemia) and therapeutic or surgical treatments (e.g., flap delay) in the presence or absence of confounding risk factors (e.g., substance abuse, irradiation, diabetes) or favorable wound-healing promoting activities (e.g., exercise). This technically challenging but feasible reconstructive surgery model eliminates inter-subject variability, while concomitantly minimizing the number of animals needed to achieve adequate statistical power. BEFAF also serves as an aid for teaching basic vascular microsurgery techniques that focus on precision, tremor management and magnification.

  • Open Access

    Biochemical Effects of Exercise on a Fasciocutaneous Flap in a Rat Model

    by Edita Aksamitiene, Adam L. Baker, Sudeep Roy, Salini Hota, Li-Hui Zhang, Julianna Rodin, Kealan Hobelmann, Jan B. Hoek, Edmund A. Pribitkin

    An overwhelming amount of data suggest that cardiovascular exercise has a positive effect on the mind and body,1 although the precise mechanism is not always clear. Several studies2-4 have found that cardiovascular exercise hastens wound healing in not only the rodent population but also humans. Indeed, the effect on humans varies from biochemical and immunologic measures to emotional and cognitive effects.5 Emery et al2 found a significant acceleration in wound healing in an elderly population after a 3-month regimen of exercise vs a sedentary control group. These studies reveal the need for further research into the mechanisms through which these effects on wound healing are achieved.


    • 1 August 2015
      • Vol. 94  (8) , 346-52

    Using ultrasonic preoperative thyroid volume to determine incision length for minimally invasive thyroid surgery.

    by Austin P Daly, Massi Romanelli-Gobbi, Jeffrey L Miller, David Rosen, David M Cognetti, Edmund A Pribitkin

    The determination of the volume of a diseased thyroid lobe or an entire gland by preoperative ultrasonography may enable surgeons to select candidates for a minimally invasive approach to thyroid lobectomy or total thyroidectomy. We retrospectively reviewed the charts of 71 adults who had undergone minimally invasive nonendoscopic thyroid surgery at our hospital from January 2007 through May 2009. We compiled data on ultrasonic preoperative thyroid volumes and operative incision lengths. Of the 71 patients, 40 had undergone lobectomy and 31 had undergone total thyroidectomy. The lobectomy group was evenly subdivided into two groups based on the median volume of the affected lobe; 20 patients had a volume of 28.32 ml. The incision length ranged from 2.0 to 3.8 cm (mean: 3.1 ± 0.53) in the smaller-volume lobectomy group and from 2.5 to 5.0 cm (mean: 3.7 cm ± 0.71) in the larger-volume lobectomy group; the difference was statistically significant (p < 0.01). The 31 patients in the total thyroidectomy group were subdivided on the basis of the median volume of the entire thyroid gland; 16 patients had a volume of 49.24 ml. The incision length in those two groups ranged from 2.5 to 4.0 cm (mean: 3.4 ± 0.53) and 3.6 to 6.0 (mean: 5.1 ± 0.99), respectively; again, the difference was statistically significant (p < 0.001). The findings of our study suggest that preoperative ultrasonographic thyroid lobe volume or total thyroid gland volume can be used to determine the appropriate minimum length for the surgical incision.


  • Decision Making for Diagnosis and Management

    by Jeffrey Bumpous, Miranda D. Celestre, Edmund Pribitkin, Brendan C. Stack

  • Sonic Rhinoplasty: Innovative Applications

    by Jewel D. Greywoode, Edmund Pribitkin

    Sonic rhinoplasty involves the use of the Sonopet ultrasonic bone aspirator (Stryker, Inc., Kalamazoo, MI, USA) to precisely sculpt the nasal bones without damage to the surrounding nasal cartilage, soft tissue, and mucosa. By employing ultrasonic waves to emulsify and remove bone under concurrent irrigation and suction, sonic rhinoplasty improves upon the conventional osteotome, drill, rasp, and powered rasp techniques that may be associated with decreased visualization, heat generation, mechanical chatter, and a lack of surgical precision with attendant soft tissue injury. We have applied this technology to bony dorsal hump and nasal spine removal, deepening of the glabellar angle and reshaping of irregular nasal contours, septoplasty, turbinate reduction, and the correction of bony asymmetries.


  • Sonic Rhinoplasty: Sculpting with the Ultrasonic Bone Aspirator

    by Edmund A. Pribitkin, Leela S. Lavasani, Carol Shindle, Jewel D. Greywoode

  • Open Access

    Minimally-Invasive Parathyroid Surgery

    by David Rosen, Joseph Sciarrino, Edmund A.